Onconetix ONCO

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

• 8-KNov. 12, 2026, 6:05 a.m. ETView on SEC.gov

  Submission of matters to a vote of security holders · Financial statements and exhibits

  AI summary, unreviewedOnconetix, Inc. shareholders approve reverse split authority (1-for-2 to 1-for-15) and Series F PIPE conversion shares at 2026 annual meeting

• 8-KNov. 9, 2026, 8 a.m. ETView on SEC.govOur explainer

  Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits

  AI summary, unreviewedOnconetix (ONCO) Effects 1-for-10 Reverse Stock Split, Cutting Shares Outstanding to About 670,000

• 425Nov. 5, 2026, 6:51 p.m. ETView on SEC.gov
• 8-KNov. 5, 2026, 6:49 p.m. ETView on SEC.gov

  Entry into a material definitive agreement · Financial statements and exhibits

  AI summary, unreviewedOnconetix amends Realbotix share exchange: Seller to own 95% of fully diluted shares if Net Cash is under $12.5 million; End Date extended to March 31, 2027

• SCHEDULE 13G/ANov. 5, 2026, 1:55 p.m. ETView on SEC.gov
• 425Oct. 27, 2026, 8:31 a.m. ETView on SEC.gov
• 8-KOct. 26, 2026, 5:04 p.m. ETView on SEC.gov

  Other events · Financial statements and exhibits

  AI summary, unreviewedOnconetix (ONCO) Announces Second 1-for-10 Reverse Split, Aggregate 1-for-100 Effective November 6, 2026

• 8-KOct. 23, 2026, 11:40 a.m. ETView on SEC.gov

  Other events · Financial statements and exhibits

  AI summary, unreviewedOnconetix, Inc. Upsizes Realbotix Grid Note Draw to $3.0 Million Outstanding With $500,000 Advance